The Venture Codex Logo

The Venture Codex

Valtruis

80 State Street, Albany, NY, 12207, United States

Overview

Valtruis, a WCAS portfolio company, provides a unique platform that invests in and partners with leaders of the health care industry.

Total investments
13
Lead investments
8
Investments · 12mo
3
Active investors
2

Sector focus

  • Business Development
  • Financial Services
  • Health Care
  • Venture Capital
Visit website

Investment portfolio

  • InStride Health

    Participated · Series C · Jun 2026

    InStride Health delivers virtual specialty outpatient care for pediatric anxiety and obsessive-compulsive disorder using cognitive behavioral therapy with a focus on exposure therapy. It provides multidisciplinary care teams—typically a therapist, an exposure coach and a psychiatrist—that develop personalized care plans and communicate with patients and families via text, phone or video. The company serves patients ages seven to 24 and currently operates in 17 states, having treated more than 5,000 patients. Reported outcomes include 97% of graduates showing overall clinical improvement and over 99% of patients remaining out of the hospital one year after discharge. Caregiver impacts reported include an 81% reduction in caregiver stress and more than 90% reporting reduced missed work. InStride aims to expand access to evidence-based specialty care while preserving its clinical outcomes as it grows into new and existing markets.

  • Nadia Care

    Led · Equity · Mar 2026

    Nadia Care operates a hybrid model combining community-centered, in-home care and virtual support delivered by Maternity Navigators and multidisciplinary care teams. Its services include care coordination, benefit sign-up and navigation, lactation support, nutrition services, and prenatal and new parent education. The company is led by CEO Adaeze Enekwechi and is based in Washington, DC. Nadia Care has served about 4,000 members and reports measurable improvements in outcomes—reductions in NICU days, low birth weight, preterm births, and emergency room visits. The recently raised $12M will be used to expand operations and advance its development efforts. The article does not disclose revenue, valuation, or prior financing details.

  • Sevaro Health

    Led · Series B · Sep 2025

    Sevaro Health provides virtual neurology services spanning the entire neurological care journey. Its core product, the Synapse AI platform, enables hospitals across the United States to expand access to neuroscience services, improve patient outcomes, and maintain long-term financial sustainability. The company is led by CEO Dr. Rajiv Narula and recently augmented its leadership team by hiring Jason Bond as Chief Financial Officer and Senior Vice President of Strategy. Sevaro Health positions itself as a partner to hospital systems, layering physician expertise with AI-driven tools to streamline neurological care delivery. The newly secured capital will fund operational scale-up and further product development. Headquartered in New York City, the company emphasizes physician leadership and technology integration as differentiators in the tele-neurology market.

  • Arbital Health

    Led · Series B · Jul 2025

    Arbital Health offers an AI-powered platform and a market-leading actuarial team that centralizes fragmented data, automates contract reconciliation, and delivers actuarially driven insights for value-based care. Its product suite includes an Adjudication Module with an Overall Risk Performance Dashboard, plus Performance Monitor and Insights modules that surface KPIs and drivers of risk. The company aims to expand payer- and provider-facing capabilities and grow its actuarial team to accelerate contract performance monitoring, management, and reconciliation across major risk models. Arbital has built a client roster of more than 40 payers, providers, digital point solutions, value-based care enablers, and integrated delivery networks, and has onboarded over 600,000 patient lives to its platform. The company emphasizes reducing administrative burden and increasing transparency to improve engagement, risk scores, and patient outcomes. Arbital was founded in 2024 and operates its team onsite in San Francisco. Arbital Health provides neutral third-party adjudication for outcomes-based contracts across the value-based care landscape, serving payers, providers, life sciences companies, employers, and digital health firms. The company’s initial product offering includes value assessment for point-solution health vendors, value analysis for payers (including employers and health plans), and actuarial advisory services. Arbital expanded its actuarial and consulting capabilities through the acquisition of Santa Barbara Actuaries, Inc., which specializes in value-based contracting, predictive modeling, and data analytics. The acquisition enables Arbital to offer a dedicated value-based care actuarial team and access to SBA’s clients. Arbital is co-founded by Travis May and Brian Overstreet. The company recently completed a $10M Series A financing to support growth and product rollout.

  • Autonomize AI

    Led · Series A · Jun 2025

    Autonomize AI offers an Agentic AI Orchestration platform with pre-trained, ready-to-deploy AI agents that coordinate as intelligent copilots across regulated healthcare workflows. The platform is healthcare-native, emphasizing explainability, human-in-the-loop workflows, and enterprise-wide orchestration rather than generic generative AI. Its agents address use cases such as care management, utilization management, benefits checks, and chart reviews, and are reported to deliver measurable operational impact at scale. Reported operating metrics include 36,000 clinical hours saved per month, 100,000+ automated care plans created monthly, and up to 50% faster decisions for prior authorizations and claims. Customers include Top 20 Pharmaceuticals, Fortune 100 healthcare enterprises, and life sciences companies. The company says it will use new funding to scale the platform and further rewire healthcare operations to reduce clinician burden and improve patient outcomes. Autonomize AI provides a secure, cloud-based AI platform optimized for healthcare and life sciences that ingests multi-modal and unstructured medical data using pre-trained medical LLMs. Its product suite includes Autonomize Pixel for clinical-trial workflows and patient matching, Autonomize Wizard for multi-modal chart insights, and generative-AI capabilities for conversational search and summarization of internal data. The platform supports fine-tuning on private data, deployment into virtual private clouds, and a privacy filter that anonymizes PII and PHI. Launched in 2022 and headquartered in Austin, Texas, the company emphasizes human-centered workflows to augment knowledge workers and improve operational efficiency. Customers report rapid ROI and efficiency gains—SubjectWell said medical-records review became ten times more efficient and accurate. Autonomize AI plans to use new funding to boost R&D and commercialization to drive down costs and accelerate adoption across healthcare organizations.

Team